The existence of specific features of Metabolic Syndrome (MetS) in psychiatric population in comparison to not psychiatric patients has not been systematically investigated. The purpose of this study is to evaluate the differences of MetS among a group of psychiatric patients and a group of internal medicine patients in terms of anthropometric measurements, biochemical variables, and cardiovascular risk.
Methods:
We enrolled 83 psychiatric inpatients under pharmacological treatment (schizophrenia n = 24, bipolar disorder n = 27, major depression n = 14, other n = 18) and 77 internal medicine patients visited for supposed MetS as affected by overweight or arterial hypertension.
Results:
Psychiatric patients differed from control subjects by age (yrs) (47 ± 9 vs. 52 ± 8.6, p = 0.001), waist circumference (cm) (111.9 ± 10.9 vs. 106 ± 12.6,p= 0.02), HDL cholesterol (mg/dl) (36.8 ± 7 vs. 48 ± 11.3, p = 0.001), serum insulin (µU/ml) (26 ± 12.5 vs. 16.4 ± 8.8, p = 0.001), triglyceride/HDL cholesterol ratio (4.8 ± 2.7 vs. 3.3 ± 2.2, p = 0.01). Female psychiatric patients had higher levels of triglycerides (mg) (178 + 86 vs. 115 + 53, p = 0.002) and of HOMA index (7.8 + 5 vs. 3.8 + 3.3, p = 0.005). Triglycerides and triglycerides/HDL ratio levels were higher in Unipolar Depression. A positive association was found between antidepressant drug treatment with triglycerides and triglycerides/HDL ratio levels, neuroleptic treatment with the HOMA index, and antipsychotics drugs with the Framingham index.
Limitations:
Psychiatric study population numerosity and duration of psychiatric illness and drug treatment.
Conclusions:
Specific features of MetS in psychiatric population are mainly represented by young age of onset, hyperinsulinemia, increased abdominal adiposity, and low HDL cholesterol whose common denominator may be insulin-resistance.
BjontorpPRosmondR. Neuroendocrine abnormalities in visceral obesity. International Journal of Obesity Related Metabolic Disorders2000;24(Suppl 2):S80–S85.
2.
MollerDEKaufmanKD. Metabolic syndrome: A clinical and molecular perspective. Annual Review of Medicine2005;56:45–62.
3.
PalmieriVOGrattaglianoIPortincasaPPalascianoG. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. Journal of Nutrition2006;136(12):3022–3026.
4.
HealdA. Physical health in schizophrenia: A challenge for antipsychotic therapy. European Psychiatry2010;25(2):S6–S11.
5.
De HertMCorrellCUBobesJCetkovich-BakmasMCohenDAsaiIDetrauxJGautamSMöllerHJNdeteiDMNewcomerJWUwakweRLeuchtS. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry2011;10(1):52–77.
6.
ColtonCWManderscheidRW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prevention of Chronic Diseases2006;3(2):A42.
7.
BobesJArangoCGarcia-GarciaMRejasJ. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophrenia Research2010;119(1–3):101–109.
8.
UcokAPolatABozkurtO. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry in Clinical Neuroscience2004;58(4):434–437.
9.
FagioliniAFrankEScottJA. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorders2005;7:424–430.
10.
HennekensCHHennekensARHollarD. Schizophrenia and increased risk of cardiovascular disease. American Heart Journal2005;150(6):1115–1112.
11.
KilbourneAMCorneliusJRHanX. Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disorders2004;6(5):368–373.
12.
GoffDCSullivanLMMcEvoyJP. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research2005;80(1):45–53.
13.
NasrallahHA. An overview of common medical comorbidities in patients with schizophrenia. Journal of Clinical Psychiatry2005;66(Suppl. 6):3–4.
14.
CohnTPrud'hommeDStreinerD. Characterizing coronary heart disease risk in chronic schizophrenia: High prevalence of the metabolic syndrome. Canadian Journal of Psychiatry2004;49(11):753–760.
15.
KatoMMCurrierMBGomezCM. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Primary Care Companion Journal of Clinical Psychiatry2004;6(2):74–77.
16.
McEvoyJPMeyerJMGoffDC. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research2005;80(1):19–32.
17.
MeyerJM. Novel antipsychotics and severe hyperlipidemia. Journal of Clinical Psychopharmacology2001;21(4):369–374.
18.
YumruMSavasHAKurtE. Atypical antipsychotics related metabolic syndrome in bipolar patients. Journal of Affective Disorders2007;98(3):247–522.
19.
ArangoCBobesJArandaPCarmenaRGarcia-GarciaMRejasJ, CLAMORS Study Collaborative Group. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophrenia Research2008;104(1–3):1–12.
20.
ReynoldsGPKirkSL. Metabolic side effects of antipsychotic drug treatment—Pharmacological mechanisms. Pharmacological Therapy2010;125(1):169–179.
21.
FavaMJudgeRHoogSLNilssonMEKokeSC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long term treatment. Journal of Clinical Psychiatry2000;61(11):863–867.
22.
BowdenCLCalabreseJRMcElroySLGyulaiLWassefAPettyFPopeHGJrChouJCKeckPEJrRhodesLJSwannACHirschfeldRMWozniakPJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry2000;57(5):481–489.
23.
ThakoreJHMannJNVlahosIMartinAReznekR. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. International Journal of Obesity Related Metabolic Disorders2002;26(1):137–141.
24.
LiebermanJA3rd. Metabolic changes associated with antipsychotic use. Primary Care Companion Journal of Clinical Psychiatry2004;6(Suppl 2):8–13.
25.
HeiskanenTNiskanenLLyytikainenRSaarinenPIHintikkaJ. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry2003;64:575–579.
26.
FordESGilesWHDietaWH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. Journal of the American Medical Association2002;287:356–359.
27.
KahlKGGreggersenWSchweigerUCordesJBalijepalliCLöschCMoebusS. Prevalence of the metabolic syndrome in unipolar major depression. European Archives of Psychiatry in Clinical Neuroscience2011;262(4):313–320.
28.
BasuRBrarJSChengappaKN. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disorders2004;6:314–318.
29.
RatliffJCPalmeseLBReutenauerELSrihariVHTekC. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics2012;54(1):67–73.
30.
McLaughlinTAbbasiFChealKChuJLamendolaCReavenG. Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine2003;139:802–809.
31.
D'AgostinoRBSrVasanRSPencinaMJWolfPACobainMMassaroJMKannelWB. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation2008;117(6):743–753.
32.
MatthewsDRHoskerJPRudenskiASNaylorBATreacherDFTurnerRC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985;28,412–419.
33.
Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association2001;285(19):2486–2497.
34.
FirstMBSpitzerRLGibbonMWilliamsJB. The structured clinical interview for DSM-IV Axis I disorders—Patients Edition (SCID-I/P, Version 2.0). New York: New York State Psychiatric Institute, 1996.
35.
OverallJEGorhamDR. The Brief Psychiatric Rating Scale. Psychology Report1962;10:799–812.
36.
HamiltonM. A rating scale for depression. Journal of Neurology and Neurosurgery Psychiatry1960;23:56–62.
37.
SpielbergerCDGorsuchRLusheneR. Manual for the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologist Press, 1970.
38.
HylerSE. Personality Questionnaire PDQ-4+. New York: New York State Psychiatric Institute, 1994.
39.
PalmieriVODe RasmoDSignorileASardanelliAGrattaglianoICardinaleGPortincasaPPapaSPalascianoG. T16189C Mitochondrial DNA variant is associated with metabolic syndrome in Caucasian subjectsNutrition2011;27:773–777.
40.
BalleriniABoccalonRMBoncompagniGCasacchiaMMargariFMinerviniLRighiRRussoFSalteriAFredianiSRossiAScatignaM, PERSEO Study Group. Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: The PERSEO (psychiatric emergency study and epidemiology) survey. Annals of General Psychiatry2007;6:29.
41.
MasandPCulpepperLHendersonD. Metabolic and endocrine disturbances in psychiatric disorders: A multidisciplinary approach to appropriate atypical antipsychotic utilization. CNS Spectrum2005;10:1–15.
42.
SalviVAlbertUChiarleASorecaIBogettoFMainaG. Metabolic syndrome in Italian patients with bipolar disorder. General Hospital Psychiatry2008;30(4):318–323.
43.
MendelsonSD. Metabolic syndrome and psychiatric illness: Interactions, pathophysiology, assessment and treatment. New York, NY: Elsevier, 2008. ISBN: 978-0-12-374240-7.
44.
ZhangJMcKeownREHusseyJRThompsonSJWoodsJRAinsworthBE. Low HDL cholesterol is associated with suicide attempt among young healthy women: The Third National Health and Nutrition Examination Survey. Journal of Affective Disorders2005;89:25–33.
45.
ChenCCLuF-HWuJ-SChangC-J. Correlation between serum lipid concentrations and psychological distress. Psychiatry Research2001;102:153–162.
46.
TeddersSHFokongKDMcKenzieLEWesleyCYuLZhangJ. Low cholesterol is associated with depression among US household population. Journal of Affective Disorders2011;135(1–3):115–121.
47.
ShivelyCARegisterTCAdamsMRGoldenDLWillardSLClarksonTB. Depressive behavior and coronary artery atherogenesis in adult female cynomolgus monkeys. Psychosomatic Medicine2008;70(6):637–645.
48.
D'AmbrosioVSalviVBogettoFMainaG. Serum lipids, metabolic syndrome and lifetime suicide attempts in patients with bipolar disorder. Progressive Neuropsychopharmacologic and Biologic Psychiatry2012;37(1):136–140. Epub 2011 Dec 30.
49.
WatanabeJSuzukiYSugaiTFukuiNOnoSTsuneyamaNSaitoMSomeyaT. The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents. General Hospial Psychiatry2012;34(5):525–528.
50.
BeumerWDrexhageRCDe WitHVersnelMADrexhageHACohenD. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology2012;37(12):1901–1911.
51.
HowrenMBLamkinDMSulsJ. Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosomatic Medicine2009;71(2): 171–186. Epub 2009 Feb 2. Review.
52.
HocaogluCKuralBAliyaziciogluRDegerOCengizS. IL-1β, IL-6, IL-8, IL-10, IFN-γ, TNF-α and its relationship with lipid parameters in patients with major depression. Metabolic Brain Disease2012;27(4):425–430.
53.
PanAKeumNOkerekeOISunQKivimakiMRubinRRHuFB. Bidirectional association between depression and metabolic syndrome: A systematic review and meta-analysis of epidemiological studies. Diabetes Care2012;35(5):1171–1180.
54.
BrownESVargheseFPMcEwenBS. Association of depression with medical illness: Does cortisol play a role?Biology and Psychiatry2004;55:1–9.
55.
BrunnerEJHemingwayHWalkerBRPageMClarkePJunejaM. Adrenocortical, autonomic, and inflamatory causes of the metabolic syndrome: Nested case-control study. Circulation2002;106:2659–2665.
56.
FraynKN. Adipose tissue and the insulin resistance syndrome. Proceedings of the Nutrition Society2001;60:375–380.
57.
HeshmatiHMTurpinGde GennesJL. Chronic hyperprolactinemia and plasma lipids in women. Klin. Wochenschr.1987;65(11):516–519.
58.
LichtCMVreeburgSAvan Reedt DortlandAKGiltayEJHoogendijkWJDeRijkRH. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. Journal of Clinical Endocrinology, and Metabolism2010;95:2458–2466.
59.
SenguptaSParrilla-EscobarMAKlinkRFathalliFKinNg YingStipEBaptistaTMallaAJooberR. Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?Schizophrenia Research2008;102(1–3):329–336.
60.
YevtushenkoOOCooperSJO'NeillRDohertyJKWoodsideJVReynoldsGP. Influence of 5-HT2c receptor and leptin gene polymorphism, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. British Journal of Psychiatry2008;192:424–428.
61.
StrineTWMokdadAHDubeSR. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. General Hospital Psychiatry2008;30:127–137.
62.
GrambschPYoungEAMellerWH. Pulsatile luteinizing hormone disruption in depression. Psychoneuroendocrinology2004;29:825–829.
63.
VaccarinoVMcClureCJohnsonBDShepsDSBittnerVRutledgeTShawLJSopkoGOlsonMBKrantzDSParasharSMarroquinOCMerzCN. Depression, the metabolic syndrome and cardiovascular risk. Psychosomatic Medicine2008;70(1):40–48.
64.
DunbarJAReddyPDavis-LameloiseNPhilpotBLaatikainenTKilkkinenABunkerSJBestJDVartiainenELoS KaiJanusED. Depression: An important comorbidity with metabolic syndrome in a general population. Diabetes Care2008;31(12):2368–2373.
65.
Salin-PascualRJAlcocer-CastillejosNVAlejo-GalarzaG. Nicotine dependence and psychiatric disorders. Review of Investment Clinics2003;55:677–693.
66.
McIntyreRSParkKYLawCWSultanFAdamsALourencoMTLoAKSoczynskaJKWoldeyohannesHAlsuwaidanMYoonJKennedySH. The association between conventional antidepressants and the metabolic syndrome: A review of the evidence and clinical implications. CNS Drugs2010;24(9):741–753.
67.
PyykkönenAJRaikkonenKTuomiTErikssonJGGroopLIsomaaB. Association between depressive symptoms and metabolic syndrome is not explained by antidepressant medication: Results from the PPP-Botnia Study. Annals of Medicine2011;44(3):279–288.
68.
MackinPBishopDWatkinsonHGallagherPFerrierIN. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. British Journal of Psychiatry2007;191:23–29.
69.
AllisonDBMentoreJL. Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry1999;156(11):1686–1696.
70.
KreyenbuhlJDickersonFB. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. Journal of Nervous and Mental Disorders2006;194(6):404–410.
71.
DaumitGLGoffDCMeyerJMDavisVGNasrallahHAMcEvoyJPRosenheckRDavisSMHsiaoJKStroupTSLiebermanJA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia Research2008;105(1–3):175–187.
72.
MeyerJKoroCEL'ItalienGJ. The metabolic syndrome and schizophrenia: A review. International Review of Psychiatry2005;17(3):173–180.
73.
MelkerssonKBerinderKHultingAL. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neurology and Endocrinology Letters2011;32(4):428–436.
